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ABSTRACT 
 
 
LNFPIII, a schistosome glycan, has been shown to induce an anti-inflammatory 
response in vivo and in vitro.  In this study we demonstrate the effects that LNFPIII has 
on macrophages using mouse models. When mice are injected with LNFPIII-dex the 
production of inflammatory cytokine IL-6 is significantly decreased, compared to 
uninjected and dextran injected mice. We also found that macrophages from LNFPIII 
injected mice show signs of alternative activation, including the upregulation of 
Arginase-1.  LNFPIII-activated macrophages also express higher levels of the surface 
markers CD80 and PDL-1. Lastly, LNFPIII- activated macrophages were able to prime T 
cells in vitro as seen by a decrease in the production of IFN-γ and IL-13.   
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BACKGROUND 
 
 
The human body is constantly subjected to infectious agents, however, usually the 
body is able to fight these infections off. The immune system acts as the body’s defense 
against a variety of pathogens. There are many mechanisms that allow the immune 
system to fight of such a wide range of diseases. The two main components of the 
immune system are the innate and adaptive systems. 
 
Innate Immune System 
The innate immune system acts as the body’s first line of defense against a 
pathogen.  This response is non-specific and can react to any pathogen that enters the 
body. This innate response uses a plethora of cells to recognize initial infection by 
foreign organisms (Janeway and Travers, 1996). Natural killer cells (NKs) are able to 
recognize antibodies on the surface of virus infected cells or tumor cells and kill them 
(Janeway and Travers, 1996). They can also kill any cell not viewed as “self”, not 
expressing MHC type receptors.  Basophils and eosinophils are commonly associated 
with parasitic infections. Upon activation, basophils release histamine that is important in 
allergic responses, and eosinophils release toxins that attack parasites (Janeway and 
Travers, 1996).  Macrophages and neutrophils are able to recognize and bind to receptors 
on foreign invaders, leading to the secretion of cytokines. Cytokines allow cells to 
communicate with one another, and often lead to an inflammatory immune response 
(Roitt et al., 2006). The innate immune system is fast acting but it displays no 
immunological memory and does not respond faster with a second infection.  Further 
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activation of the adaptive immune system is needed to increase protection (Kimball, 
2007). 
 
Adaptive Immune System 
Unlike the innate immune system, the adaptive immune system is activated four 
to five days after infection (Janeway and Travers, 1996). In this response, lymphocytes (T 
cells and B cells) react only to specific foreign antigens (Roitt et al., 2006). The adaptive 
immune system also displays immunological memory so that a pathogen will not infect 
the body twice (Janeway and Travers, 1996). The innate and adaptive immune systems 
must work together in order to develop an appropriate immune response. The link 
between innate and adaptive immunity is provided by antigen presenting cells. 
 
Antigen Presenting Cells 
Antigen presenting cells (APC’s), as representatives of the innate immune system, 
provide the secondary signal needed to induce an adaptive immune response by T cell 
activation (Janeway and Travers, 1996). The three types of APC’s are macrophages, 
dendritic cells (DC’s) and B cells. Since T cells are unable to recognize antigens directly, 
APC’s are able to internalize antigens, process them, and present them to T cells in a 
recognizable form (Figure 1) (Roitt et al., 2006). APCs internalize antigens either by 
phagocytosis or recognition of Pathogen Associated Molecular Patterns (PAMPS), such 
as LPS, by Toll-Like Receptors (TLR’s) (Thomas and Harn, 2004). The antigen is 
processed inside of the cell then presented to the T cell in one of two ways. In the first 
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way, T cell Receptors (TCR) recognize the Major Histocompatability Complex (MHC), 
which presents the antigen (peptide) (Kimball, 2007). 
 
Figure 1.  The Link Between Innate and Adaptive Immunity.  Antigen presenting cells (yellow), 
representing the innate immune system, process and present foreign antigens to naïve T cells (blue), 
representing the adaptive immune system.  (Dana Farber Cancer Institute, 2007). 
 
In the second way, costimulatory molecules act as a second signal (Figure 2). 
Receptors on the surface of the T cell recognize certain co-stimulatory molecules 
expressed on the APC’s surface. This can be seen in the figure with the CD 28/B7 
complex, and also includes the CD40/CD40L complex, the ICOS/ICOS-L complex, and 
others.  Naive T Cells can mature into effector T cells such as CD4+ T Helper Cells (Th1 
or Th2 type) or CD8+ Cytotoxic T cells (Kimball, 2007). 
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Figure 2. The Use of Costimulatory Molecules by Antigen Presenting Cells.  In 
this instance the co-stimulatory molecules are represented by the CD28/CD80/86 
interaction shown in the lower right (Kochar 2006). 
 
T Helper Cell Immune Responses 
There are two types of immune responses led by mature, CD4+ T helper cells: the 
Th1 type induces a pro-inflammatory response by producing mediators such as interferon 
gamma (IFN-), TNF-α, Interleukin – 12 (IL-12), and IL-2. The Th2 type induces an anti-
inflammatory response by producing IL-4, IL-5, IL-13, and IL-10 (Thomas and Harn, 
2004). It has been shown that the binding of PAMPs such as LPS to Toll-Like Receptors 
(TLRs) activates dendritic cells and macrophages to induce these differential immune 
responses (Medzhitov, 2001). Much is known about the activation of DC1s (DCs that 
induce a Th1 response), but until recently, little was known about the activation of DC2s. 
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Classically and Alternatively Activated Macrophages 
In response to pathogens, two types of macrophages can arise. Classically 
activated macrophages (CAMph) develop in response to Th1 type mediators such as IFN-
  and TNF (Edwards et al, 2006) and most other antigens including LPS and CpG. 
Following the binding of PAMPS to CAMph surface receptors and the induction of 
signal transduction events, LPS and other PAMPS are taken into the cell, where they are 
degraded (Edwards et.al 2006). A CAMph response is characterized by an increase in 
iNOS activity in macrophages (De’Broski et al., 2004). The secretion of nitrogen by these 
cells kills pathogens and induces an inflammatory response. However, in some cases, the 
inflammatory response can lead to apoptosis and severe tissue damage (Edwards et al 
2006).  CAMph have been shown to respond to immunodeficiency syndromes such as 
AIDS as well as autoimmune diseases (Edwards et al., 2006). Upon activation, CAMph 
express many surface markers such as CD80, CD86, MHC II, ICOS-L and PD-L1 
(Kuipers et al., 2006). They are also known to secrete cytokines such as IL-6, TNF, and 
IL-1 (Gordon, 2003). 
In contrast to CAMph, alternatively activated macrophages (AAMph) develop in 
response to the Th2 type cytokines, IL-4 and IL-13 (Gordon, 2003). This response is 
commonly seen in allergic response to parasite infection and asthma. Alternative 
activation of macrophages is characterized by the upregulation of Arginase-1, which is a 
key factor in granuloma formation (Gordon, 2003). It is also thought to promote growth 
of the extracellular matrix (Martinez et al., 2008).  Activation of AAMph leads to an anti-
inflammatory response, while promoting cell proliferation. They are able to activate T 
cells by cell-cell interaction and by cytokine production. Some studies have shown 
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AAMph to have a deactivating effect on T cells (Gordon, 2003). The surface markers 
CD80 and PDL-1 have been associated with macrophage activation and maturation 
(Martin-Orozco et al., 2006; Keir et al., 2006; Nakanishi et al., 2007). Although the topic 
is still under debate, it is thought that these markers act as inhibitors to a T cell response 
(Liang et al., 2003; Zhao et al., 2007; Kuipers et al., 2006).  Other markers such as YM-1, 
FIZZ-1, MGL-1, and the mannose receptor (MMR) have also been associated with 
alternative activation (Raes et al., 2002). The secretion phenotype of AAMph cells is still 
unidentified. Figure 3 compares classical versus alternative macrophage activations. 
 
 
Figure 3.  Comparison of Classical versus Alternative Activated Macrophages.  Picture Adapted from 
Gordon, 2003) 
 
Lacto-N-Fucopentaose III 
Studies have shown that helminth parasite infection leads to a Th2 type, anti-
inflammatory response (Okano et al., 1999; Okano et al., 2001; Thomas et al., 2003; 
Thomas and Harn, 2004).  It was shown that individuals infected with the schistosoma 
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parasite are least likely to develop atopic diseases (Yazdanbakhsh et al., 2002; Thomas 
and Harn, 2004;). It was also shown that antibodies developed against the parasite 
contain the Lewis
x
 trisaccharide, which is commonly found on schistosome eggs 
(Harrison and Ridley, 1975; Nash, 1978; Nash et al., 1978; Okano et al., 1999; Thomas 
and Harn, 2004).  It has been shown that Lewis
x
 containing sugars bind to C-type Lectin 
(CTL) receptors, such as DC-SIGN, the mannose receptor (MMR), and MGL, that are 
expressed on dendritic cells and macrophages (Van Leimpt et al., 2006). 
 The Th2 immune response was found to be driven by schistosome glycans 
(Thomas and Harn, 2004). One glycan of interest is the polysaccharide Lacto-N-
fucopentaose III (LNFPIII). LNFPIII contains the Lewis
x
 trisaccharide and can be found 
during natural immunosuppressive situations such as pregnancy and cancer, and also in 
human breast milk, and in the urine of pregnant women (Erney et al., 2001; Kedler et al., 
2001; Pfeninger et al., 2001; Thomas and Harn, 2004). Other glycans, such as LNnT, that 
do not contain the Lewis
x
 trisaccharide, do not display the Th2 type response, suggesting 
that the Lewis
x
 trisaccharide plays an important role in the Th2 pathway (Thomas and 
Harn, 2004). LNFPIII has been shown to aid in the prevention of some autoimmune 
diseases such as psoriasis (Atochina and Harn, 2006), diabetes (Maron et al., 1998), and 
colitis (Elliot et al., 2003).  
It has been shown that LNFPIII induces a Th2 type response in vitro, however the 
mechanism by which LNFPIII activates macrophages in vivo is unclear. Little is known 
about the profile of cytokine secretion induced by LNFPIII. The profile of LNFPIII 
induction of alternative activation is also unknown. The understanding of how LNFPIII 
works in vivo is crucial to the use of this sugar for the treatment of diseases.  
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In our studies, LNFPIII (βGal-[1-4]-(αFuc-[1-3])-βGlcNAc-[1-3]-βGal-[1-4]-Glc) 
was conjugated to a 40 kDa molecule of dextran (Dex), which is used as a carrier 
molecule (Figure 4). The glycoconjugate consisted of ~12 LNFPIII molecules conjugated 
to a 40 kDa molecule of Dex. 
 
Figure 4.  Diagram of Lacto-N-fucopentaose III Structure (Thomas and Harn, 2003).   
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PROJECT PURPOSE 
 
 
The mechanism by which LNFPIII leads to a Th2 type response is still unclear. It 
has been shown that LNFPIII induces a Th2 type anti-inflammatory response in vitro. 
However, the role that LNFPIII plays in activating macrophages in vivo is not known. 
The purpose of this study is to demonstrate the effects that LNFPIII has on macrophages 
using mouse models. First, we investigated the effects of LNFPIII on macrophage 
production of cytokines and chemokines by using a Mouse Cytokine Array and by 
ELISA assay. Next, we investigated signs of alternatively activated macrophages 
including Arginase-1 by western blot, and surface markers CD80 and PD-L1 by FACS 
analysis. Lastly, we investigated LNFPIII’s ability to activate T cells in vitro by co-
culture of PECs and T cells.  
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METHODS 
 
 
Carbohydrates 
The polysaccharide Lacto-N-fucopentaose (LNFPIII) was obtained from Dr. 
David Norberg, Sweden. LNFPIII (βGal-[1-4]-(αFuc-[1-3])-βGlcNAc-[1-3]-βGal-[1-4]-
Glc) was conjugated to a 40 kDa molecule of dextran (Dex). The glycoconjugate 
consisted of ~12 LNFPIII molecules conjugated to a 40 kDa molecule of Dex. 
Mice 
Six to eight week old, female, BALB/c,  Black/6, DC Sign 
-/-
, Gal 1/3 
-/-
, and 
DO11.10 mice were purchased from Jackson Laboratory (Bar Harbor, ME) and were 
maintained under pathogen-free conditions at the Harvard School of Public Health animal 
facility. The mice were injected intraperitoneally with 100 µg of LNFPIII-Dex in 200 µl 
of PBS for 24-48 hours. 
Isolation of Peritoneal Cells and Splenocytes  
Approximately 24 hours post injection with LNFPIII-dextran or dextran, mice 
were euthanized by CO2 inhalation. Peritoneal endothelial cells (PECs) were collected by 
lavage under sterile conditions by injecting 5 ml of PBS into the peritoneal cavity.  
The spleen was extracted from DO.11.10 mice. Cells were collected in 5 ml PBS 
and lysed in 1 ml Boyle’s solution. CD4+ T cells were collected by MACS purification 
(Mitenyi Biotech). Cells were resuspended in MACS buffer and incubated with CD4 
microbeads for 15 minutes at 4°C. CD4+ cells were separated magnetically using a 
MACS column and separator.  
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Cell Culture 
PECs were cultured at an initial density of 1.0 X 10
6
 cells/ml in RPMI 1640 
medium (Invitrogen), supplemented with 10% Fetal Bovine Serum (HyClone, Logan 
UT), 100 U/ml streptomycin, 100 U/ml penicillin, 2 mM glutamine (Sigma-Aldrich) and 
0.05 mM 2-Mercaptoethanol (Gibco). Cells were cultured in 24 or 48 well plates for 48 
hours at 37°C. Supernatants were collected for analysis.  
 
Macrophage-T cell co-culture 
PECs were plated at a concentration of 0.5 X 10
6
 cells/ml in 0.5 ml of complete 
media in 48 well plates for 1 hour at 37°C with 1000 or 100 nM of OVA peptide (OVA 
223-239 peptide; Sigma-Genosys, Woodlands, TX). Splenocytes from DO.11.10 mice 
were collected and added to the PEC culture in the same volume and concentration for 72 
and 96 hours. Supernatant was collected for analysis by ELISA.  
 
ELISA 
The levels of TGF-β, IL-13, IL-6, and IFN-γ (BD Biosciences) were determined 
by capture ELISA according to the manufacturer’s protocol. Briefly, capture antibodies 
were diluted in the appropriate antibody diluents. 96 well plates (Nalge Nunc 
International) were coated with capture antibody at 0.5 μg/ml, 1 μg/ml, 2 μg/ml, and 4 
μg/ml respectively and incubated overnight at 4C. Plates were washed in buffer 
containing PBS and 0.05% Tween-20. The plates were then blocked in buffer containing 
1% BSA in PBS for 1 hour and then washed. Plates were incubated with samples and 
standards for 2 hours at room temperature or overnight and then washed. Next, the plates 
were incubated in secondary biotinylated antibodies at 0.5 ng/ml, 1 μg/ml, 2 μg/ml and 4 
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μg/ml, respectively, for 2 hours at room temperature and then washed. Lastly, the plates 
were incubated in streptavidin HRP (1:2000 dilution, R&D systems) for 1 hour at room 
temperature and washed. The samples were developed with TMB substrate solution 
(Kirkegaard and Perry Laboratories), and the reaction was stopped with 5% phosphoric 
acid. The optical density was read at 450 nm on a Spectramax 190 using softmax PRO 30 
alias software. Cytokine concentration was calculated based on the standard curve. 
 
Cytokine Array 
The levels of 62 soluble protein molecules were determined by a Mouse Cytokine 
Antibody Array Kit (RayBiotech). Membranes were blocked in blocking buffer, provided 
by the kit for 30 minutes at room temperature. The membranes were then incubated with 
samples overnight at 4°C. Next, the membranes were washed 5x5 minutes with wash 
buffer. The membranes were incubated in primary antibody for 2 hours at room 
temperature.  Membranes were washed and then incubated in HRP for 2 hours. Lastly, 
the membranes were washed, incubated in detection buffer for 2 minutes, and the image 
was captured on a Kodak Imager.   
 
Western Blots 
Cells were harvested in 100 μl of SDS sample buffer, containing Laemelli sample 
buffer and 2-ME (Bio Rad). Standard western blot protocol was performed. The samples 
were run on a 4-20% Tris-HCl gel (Bio Rad) and transferred onto an Immobilon Transfer 
Membrane (PVDF) (Millipore). The membranes were blocked in 5% milk / 1X TBS-
0.1% Tween-20 for 1 hour at room temperature. The membrane was incubated with 
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Arginase-1 antibody (BD Biosciences), or total ERK antibody (Cell Signaling), overnight 
at 4C. The membrane was incubated with anti- mouse IgG antibody (Cell Signaling) and 
anti rabbit-HRP conjugated antibody (Cells Signaling) respectively for 1 hour at room 
temperature. The blots were developed with chemiluminescent HRP substrate (Pierce). 
The image was captured on a Kodak IS440CF Imaging Station with Kodak ID software.  
 
FACs Analysis 
Cells were harvested in FACS buffer (PBS containing 0.1% BSA and 0.1% 
sodium azide) and 0.5 X 10
6
 cells in 100 µl were stained for 30 min at 4°C. Cells were 
stained with F4/80 Antibody (Serotec) – APC labeled, PD-L1-PE, and CD80-PE (BD 
Biosciences). Cells were washed twice in FACS buffer and analyzed on FACS caliber 
machine using CellQuest software. 
 
Statistical Analysis 
Statistical significance of difference among groups was determined by a Student’s 
t-test. All data are expressed as the mean ± one standard error. 
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RESULTS 
 
LNFPIII significantly decreases cytokine production  
In order to determine the effect of LNFPIII on macrophages in vivo, we first 
investigated the cytokine production of peritoneal endothelial cells (PECs) obtained from 
mice injected with LNFPIII versus uninjected mice. To do so, we injected Balb/c mice 
with 100 µg of LNFPIII-dex, a dose previously determined in another study.  Twenty-
four hours post injection, PECs were collected and plated for 48 hours in complete media 
without additional stimulation. We then performed a Mouse Cytokine Antibody Array on 
supernatant from the cultured cells. We found that at least 4 cytokines/chemokines, IL-6, 
IL-10, KC (chemokine CXCL1), and LIX (chemokine CXCL5), were down regulated in 
the array of LNFPIII-activated PECs compared to the control PECs from uninjected mice 
(Figure 5a). After quantitatively analyzing the blots, we determined that IL-6, IL-10, and 
KC were significantly decreased in PECs from LNFPIII injected mice, whereas the 
decrease in LIX, a Th-1 type chemokine was not significant (Figure 5b). Surprisingly, we 
did not find any up regulated molecules among the 62 analyzed 
cytokine/chemokine/soluble molecules.  
To confirm our data from the Mouse Cytokine Antibody Array, we performed an 
IL-6 and IL-10 combined ELISA using the same supernatants, and found that the level of 
IL-6 in PECs from LNFPIII-dex injected mice was indeed significantly reduced 
compared to control mice (Figure 5c). We were not able to confirm IL-10 data by ELISA 
because of low antibody sensitivity, and anti-KC and anti-LIX antibody are not available 
for ELISA assay. Thus, using an ELISA we confirmed our Cytokine Array data that IL-6 
is significantly down regulated in PECs from LNFPIII injected mice.  
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A. 
   
         
B. 
     
C. 
 
Figure 5. (a) Cytokine Array shows levels of IL-6 (outlined in red), IL-10 (outlined in green), KC 
(outlined in yellow), and LIX (outlined in blue) proteins in the conditioned medium of 48 hr cultured 
PEC cells isolated from uninjected mice. (b) Analysis of Cytokine Array shows that IL-6, IL-10, and 
KC proteins are down regulated (3 significantly) in LNFPIII injected mice.  (c) IL-6 ELSIA confirms 
that IL-6 is significantly down regulated in cultured PECs from LNFPIII injected mice.   * p < 0.05 
for LNFPIII versus control. 
* 
* 
* 
* 
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Cytokine production of LNFPIII-activated PECs from different strains of mice 
 
We next asked whether the mouse strain is important for the LNFPIII response. 
We chose to study Balb/c mice, known for a predominantly Th2 type immune response 
versus Black/6 mice, which are known for a Th1 type response. Since it is known that the 
Lewis
x
 trisaccharide binds to C-type Lectin receptors such as Galectin 1 and 3, DC-
SIGN, Mannose Receptors, and MGL receptors, we decided to use two strains of 
knockout mice, Galectin 1/3, and DC SIGN, to determine the effect of LNFPIII on 
cytokine production. Similar to previous experiments, we injected the mice with LNFPIII 
for 24 hours and plated peritoneal cells for 48 hours. We collected the supernatant and 
performed IL-6 and TGF-β ELISAs on these samples. We found that IL-6 was 
significantly decreased in all samples of PECs from LNFPIII injected mice except for Gal 
1/3 knockout mice (Figure 6a).  To eliminate the suggestion that LNFPIII caused cells to 
go through apoptosis, we tested for TGF-β, a cytokine that is known to be present in both 
Th1 and Th2 type responses. There was no significant increase or decrease in any of the 
samples (Figure 6b). We conclude that LNFPIII can decrease the production of IL-6 
independent of Balb/C or Black/6 genetic background and in DC SIGN-deficient mice, 
but not in Galectin 1/3 deficient mice. 
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A. 
 
 
B. 
 
Figure 6. (a) IL-6 is significantly down regulated relative to control in all strains of mice except the 
Gal 1/3 deficient mice (b) There is no significant decrease in TGF -β in all samples. * p < 0.05 for 
LNFPIII versus control. 
 
Arginase-1 is up regulated in LNFPIII injected mice 
 
We next investigated if macrophages show signs of alternative activation after 
LNFPIII injection. We injected Balb/c mice with LNFPIII-dex for 24 hours, harvested 
peritoneal cells, and performed a western blot analysis for Arginase-1 as a marker protein 
for an alternative activation response. We found that Arginase-1 is significantly up 
regulated in PECs from LNFPIII injected mice compared to the controls (Figure 7).  
These results suggest that LNFPIII induces alternative activation of macrophages. Since 
* 
* 
* 
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there are other known markers for AAMph, such as YM-1, FIZZ-1, MMR, and MGL-1, 
in the future we will perform the experiments to investigate the alterations of those 
markers after LNFPIII activation of macrophages using RT-PCR.  
 
Figure 7. Western blot analysis of Arginase 1 in PECs obtained from uninjected mice (lane 1), 2hrs 
Dex injected mice (lane 2), 2 hrs LNFPIII-dex injected mice (lane 3), 20 hrs LNFPIII-dex injected 
mice (lane 4). PECs stimulated with 20 ng/ml rmIL-4 (lane 5) and 1ug/ml LPS+20ng/ml IFN-γ (lane 
6) for 20 hrs were used as positive controls. The same blot was stripped and reprobed with anti-Erk 
antibody as a loading control. The expression of the MAP kinase Erk is activated in response to most 
PAMPS such as LNFPIII and LPS, leading to transcription.  
 
Activation of PECs by LNFPIII in vivo is IL-4 and IL-13 independent   
 
Alternatively activated macrophages are commonly associated with IL-4 and IL-
13 production. CD4+ T cells and eosinophils can secrete IL-4 and IL-13 to activate 
macrophages. To determine if LNFPIII macrophage activation is IL-4/IL-13 dependent, 
we used IL-4 Receptor alpha knockout mice (IL-4 Rα KO) because IL-4 and IL-13 share 
the same receptor on macrophages. We injected IL-4 Rα KO mice with LNFPIII-dex, and 
dextran for 24 hours and cultured the peritoneal cells for 48 hours in vitro without 
additional stimulation. We collected the supernatant for IL-6 and TGF-β ELISAs. We 
found no difference in the production of IL-6 or TGF-β for the IL-4 Rα KO mice 
compared to control Balb/c mice (Figure 8a,b). This suggests that activation of 
macrophages by LNFPIII in vivo is IL-4 and IL-13 independent.    
 1     2      3     4     5      6 
Arginase I 
Total Erk 
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A.  
 
 
 
B.  
 
Figure 8 (a) IL-6 is significantly decreased in LNFPIII injected mice for both wild type and IL-4 Rα 
KO mice. (b). There is no significant decrease in TGF-β produced in either wild type or IL-4 Rα KO 
mice injected with LNFPIII. * p < 0.05 for LNFPIII versus control. 
 
 
PECs from mice injected with LNFPIII-dex express CD80 and PD-L1 surface markers  
 
We next investigated the expression of macrophage surface markers that are 
associated with macrophage activation and maturation. We injected Balb/c mice with 
LNFPIII-dex for 24 hours, collected PECs, washed and stained them with F4/80 (specific 
mouse macrophage marker) and PD-L1 and CD80 (markers associated with macrophage 
activation and maturation). We did the same for IL-4 Rα KO mice to validate our 
* * 
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findings from the cytokine data. We found that both Balb/c wild type and IL-4 Rα KO 
mice up regulated both PDL-1 and CD80 markers (Figure 9) following LNFPIII 
treatment. This suggests that LNFPIII injected mice express surface markers associated 
with alternative activation and also confirms that the IL-4 receptor is not necessary for 
the function of LNFPIII.  
PD-L1 CD80
BALB/c mice
IL-4 R KO mice
 
Figure 9. PDL-1 and CD80 expression on F4/80+ macrophages of dextran injected (control) versus 
LNFPIII injected (bold line) mice. 
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IFN-γ and IL-13 are significantly decreased in supernatants from co-cultures of T cells 
and PECs from LNFPIII injected mice 
 
Since we know that macrophages show signs of alternative activation after mice 
have been injected with LNFPIII, we wanted to determine the effect this sugar has on 
macrophage’s ability to activate T cells in vitro. We injected Balb/c mice with LNFPIII–
dex for 24 hours and co-cultured the isolated macrophages for 72 or 96 hours with 
splenocytes from DO.11.10 mice in the ratio of Macrophages to T cells 1:1 and 1:5 in the 
presence of either 100 or 1000 nM of OVA peptide. We found a dose dependent response 
of CD4+ T cells to the peptide, where IFN–γ secretion was significantly decreased in co-
cultured PECs from LNFPIII injected mice (Figure 10a,b). We also tested a Th-2 type 
cytokine, IL-13, and found that it is also significantly decreased in the same samples 
(Figure 10c). We did not find any secretion of IL-4 or IL-5. From this data we were able 
to determine that LNFPIII is able to activate macrophages in vivo, and co-culture of those 
macrophages with CD4+ T cells from DO.11.10 mice in the presence of OVA peptide 
induced a decrease in the Th1 type cytokine IFN-γ. Surprisingly, we also found that a 
Th2 type cytokine, IL-13, was significantly decreased as well. This suggests that LNFPIII 
activated macrophages are slowing down the production of T cell cytokines.   
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A.                                                                        B. 
 
 
 
C.                                                                        D.  
         
Figure 10. 72 hour (a) and 96 hour (b) macrophage/splenocyte co-culture shows an OVA peptide dose 
dependent decrease in IFN-γ production of T cells and PECs from mice injected with LNFPIII. Ratio 
of macrophages to T cells (1:1 and 1:5) has no effect on the dose dependent decrease of IL-13 to 100 
nM (c), or 1000 nM (d) of OVA peptide.  *p< 0.05 for LNFPIII versus control. 
 
* 
* 
* 
* 
* 
* 
* 
* 
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DISCUSSION 
 
 
Previously, it had been shown that LNFPIII-activated Antigen Presenting Cells 
(APCs) induce a Th2 type, anti inflammatory response, characterized by a decrease in 
IFN-γ and an increase in IL-4 production by T cells in vitro (Thomas et al., 2003; 
Thomas and Harn 2004). Atochina and Harn demonstrated that peritoneal macrophages 
secreted IL-10, PGE2 and TNF-α upon in vitro stimulation with LNFPIII (Atochina and 
Harn, 2005). In this study, we investigated the mechanism of how LNFPIII activates 
macrophages in vivo.  
In response to pathogens, macrophages can become either classically or 
alternatively activated. Classically-activated macrophages, which have been well 
characterized, respond to Th1 type mediators such as IFN- (Edwards et al, 2006). They 
are characterized by an increase in iNOS activity (De’Broski et al., 2004).  Much less is 
known about alternatively activated macrophages. It has been shown that alternatively 
activated macrophages respond to the Th2 type mediators IL-4 and IL-13 (Gordon, 
2003). It is well known that macrophages induce T cells to secrete IL-12 and IFN-γ upon 
stimulation with LPS, a Th1 type promoter (Thomas et al., 2003; Dillon et al., 2004), and 
IL-4, IL-5, IL-13, and IL-10, in response to LNFPIII (Thomas et al., 2003). Studies have 
shown secretion of IL-6 in both Th1 and Th2 type responses (Diehl and Rincón, 2002). In 
our current study, using a Mouse Cytokine Antibody Array, we found that the production 
of the cytokines, IL-6 and IL-10, and the chemokine KC were decreased in PECs 
collected from LNFPIII-injected mice compared to controls. KC, or CXCL1, is 
associated with a group of chemokines that are up regulated in cancer patients (Bièche et 
al., 2007).  LNFPIII has been found to be present in cancer cells and may be acting to 
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inhibit the production of these chemokines in vivo. We confirmed the reduction of IL-6 
secretion in PECs from LNFPIII-injected mice by ELISA. Thus we can conclude that 
LNFPIII has a negative effect on macrophage production of cytokines when injected in 
vivo.  
We validated our LNFPIII-induced secretion of IL-6 from PECs, in different 
strains of mice by ELISA. In this study, we found similar decreased levels of IL-6 in 
Balb/c mice, known for a predominately Th2 type response, and Black/6 mice, known for 
a predominately Th1 type response. Our results indicate that LNFPIII is able to function 
normally even in a predominately inflammatory environment. LNFPIII contains the 
Lewis
x
 trisaccharide, which is known to bind to C-type Lectin receptors such as DC- 
SIGN, MGL-1, MMR, and Galectins (Van Leimpt et al., 2006).  It was hypothesized that 
by eliminating LNFPIII’s ability to bind to these receptors, the sugar would not be able to 
function. We found no difference in the LNFPIII-induced decrease of IL-6 production 
from PECs of DC-SIGN and Galectin 1/3 knockout mice compared to control mice. 
These results suggest that when one of those receptors is not present, LNFPIII binds to 
other available receptors, such as the mannose receptor (MMR) or MGL-1. The levels of 
TGF-β were not altered by the LNFPIII treatment in any of the mice, confirming that the 
decrease in cytokine production is not due to apoptosis.  
Since a Th2 type response is associated with alternative activation, we 
investigated whether LNFPIII induces the expression of markers associated with 
alternative activation such as the upregulation of Arginase-1 (Gordon, 2003; Martin-
Orozco et al., 2006; Keir et al., 2006; Nakanishi et al., 2007). We found an upregulation 
of Arginase-1 in PECs from LNFPIII injected mice compared to control mice. Based on 
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these results, we conclude that macrophages from LNFPIII injected mice portray the 
profile of alternative activation. Although other markers have also been associated with 
alternative activation, such as FIZZ-1, Ym1, and MGL-1, we did not test for these 
markers since studies have shown that the presentation of these markers on AAMph is 
not consistent (Raes et al., 2002; Raes et al., 2005; Donnelly et al., 2005; Reece et al., 
2006).  Future studies will be done using RT-PCR to investigate the expression of these 
markers in macrophages from LNFPIII injected mice.  
Classically-activated macrophages express costimulatory molecules such as 
CD80, CD86, MHC II, ICOS-L, and PD-L1 on their surface. The expression of these 
markers has been associated with macrophage activation and maturation (Kuipers et al., 
2006). PD-L1 and CD80 have been described as inhibitory molecules (Brown et al., 
2003; Ito et al., 2005; Kuipers et al., 2006). Studies have shown that splenic DCs in vivo 
and bone marrow DCs from tumor bearing mice induce the expression of PD-L1 and 
CD80 (Idoyaga et al., 2007).  In our study, we found an upregulation in the expression of 
the surface markers PD-L1 and CD80 on F4/80+ macrophages from LNFPIII injected 
mice compared to controls. This data suggests that LNFPIII induces expression of 
inhibitory molecules, similar to those induced by cancer cells.  
The cytokines IL-4 and IL-13 are commonly associated with alternative activation 
(Gordon, 2003; Anthony et al., 2006). The production of IL-13 has been directly 
associated with the induction of alternatively activated macrophages characterized by 
Arginase-1 expression, although Arginase-1 is not always associated with IL-13 (Munder 
et al., 1998; Prasse et al., 2007). Studies have shown that alternative macrophage 
activation is dependent upon IL-4 and IL-13 production (De’Broski et al., 2004). Since 
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IL-4 and IL-13 share the common receptor on macrophages, in the current work we used 
IL-4Rα KO mice to rule out the role of both cytokines in generating alternatively 
activated macrophages by LNFPIII in vivo. We demonstrate that IL-4 Rα KO display 
similar profiles of activation (IL-6 production and PDL-1/CD80 expression) as control 
mice, suggesting that LNFPIII activation is independent of IL-4/IL-13. Although IL-4 
and IL-13 are commonly associated with alternative activation, our work suggests that 
the increase of these cytokines is merely a product of alternative activation and not 
important for this development in our experimental model.   
In vivo, macrophages activate T cells to induce certain immune responses. In 
order to mimic this, we co-cultured macrophages, with T cells that respond to the OVA 
peptide. We detected a decrease in the production of IFN-γ from T cells co-cultured with 
PECS from mice injected with LNFPIII, which is typical in a Th2 type response. 
However, we also determined a significant decrease in IL-13 secretion (Figure 10), which 
is typically increased in a Th2 type response (Thomas and Harn, 2004).  Since we found 
an upregulation in the expression of the inhibitory molecules PD-L1 and CD80 on 
LNFPIII-stimulated macrophages, it is possible that surface markers expressed in 
alternatively activated macrophages are able to deactivate cytokine production, leading to 
a Th-2 type response. Keir et al has suggested that PD-L1 acts as an inhibitor to T cell 
response, however this idea is still under debate (Liang et al., 2003; Kuipers et al., 2006; 
Zhao et al., 2007). We were not able to detect IL-4 and IL-5 production in the co-cultured 
samples. A longer co-culture may be necessary in order to detect cytokines that may be 
produced later in culture. 
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 Alternative activation of macrophages is important for the development of 
immune responses against allergic diseases and parasitic infections. Our data indicate that 
LNFPIII induces the alternative activation of macrophages characterized by upregulation 
of Arginase-1.  Furthermore, the data suggests that expression of the surface markers PD-
L1 and CD80 leads to the deactivation of T cell production of cytokines as a method of 
inducing a predominantly Th2 type response. Our work represents findings that add to the 
understanding of this alternative activation process and will someday make an impact of 
the treatment of diseases. 
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